Robert J. Kelley - 07 Apr 2023 Form 4 Insider Report for Talis Biomedical Corp

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 07 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Apr 2023, 16:06:18 UTC
Prior SEC filing: 02 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Gillian Green, Attorney-in-fact for Robert J. Kelley

Key filing fact

Robert J. Kelley filed Form 4 for Talis Biomedical Corp on 11 Apr 2023.

Key facts

This page summarizes Robert J. Kelley's Form 4 filing for Talis Biomedical Corp.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Apr 2023, 16:06.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TLIS transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 07 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.4900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date of March 1, 2023 and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.